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Abstract: Detection of epithelial ovarian cancer (EOC) poses a critical medical challenge. However,
novel biomarkers for diagnosis remain to be discovered. Therefore, innovative approaches are
of the utmost importance for patient outcome. Here, we present a concept for blood-based
biomarker discovery, investigating both epithelial and specifically stromal compartments, which
have been neglected in search for novel candidates. We queried gene expression profiles of EOC
including microdissected epithelium and adjacent stroma from benign and malignant tumours. Genes
significantly differentially expressed within either the epithelial or the stromal compartments were
retrieved. The expression of genes whose products are secreted yet absent in the blood of healthy
donors were validated in tissue and blood from patients with pelvic mass by NanoString analysis.
Results were confirmed by the comprehensive gene expression database, CSIOVDB (Ovarian cancer
database of Cancer Science Institute Singapore). The top 25% of candidate genes were explored for their
biomarker potential, and twelve were able to discriminate between benign and malignant tumours
on transcript levels (p < 0.05). Among them T-cell differentiation protein myelin and lymphocyte
(MAL), aurora kinase A (AURKA), stroma-derived candidates versican (VCAN), and syndecan-3
(SDC), which performed significantly better than the recently reported biomarker fibroblast growth
factor 18 (FGF18) to discern malignant from benign conditions. Furthermore, elevated MAL and
AURKA expression levels correlated significantly with a poor prognosis. We identified promising
novel candidates and found the stroma of EOC to be a suitable compartment for biomarker discovery.
Keywords: biomarker discovery; ovarian cancer; tumour microenvironment; differential expression
1. Introduction
Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death in women in
developed countries [1]. EOC is commonly referred to as the ‘silent killer’ due to a lack of specific
symptoms that commonly leads to a diagnosis at a late and advanced stage with a 5 year survival rate
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of less than 40%. This 5 year survival rate, however, increases to over 90% when EOC is diagnosed at
an early stage [2]. Hence, novel approaches to detect EOC earlier have great potential to achieve a
meaningful impact on patient survival.
It is now known that ovarian cancer is a very heterogenous disease, with the major histological
subtypes, serous, clear cell, endometriod, and mucinous, characterised by different somatic alterations
and clinical etiologies. Since most identified tissue-based biomarkers differ significantly between
subtypes [3], histology is important and has implications for biomarker studies. Nevertheless, even
though the source of cell-of-origin and underlying biological mechanisms might differ considerably
between the subtypes, common features, e.g., changes of the tumour microenvironment of the
peritoneum in response to malignant transformation, are shared, and the most recently identified
markers of the chloride intracellular channel (CLIC) protein family, CLIC1 and CLIC4, showed
promising potential as serum and tissue biomarkers across all subtypes of EOC [4]. Biomarkers include
gene expression products, metabolites, circulating nucleic acids characterised by somatic mutations,
and splice variants [5–10]. The potential of microRNA signatures in the diagnosis and prognosis of
ovarian cancer has been especially described in recent years [11–14]. Nevertheless, cancer antigen
125 (CA125) remains the most frequently used blood-based biomarker for ovarian cancer. However,
CA125 can also be elevated in common benign gynaecological conditions, such as endometriosis,
follicular cysts, and cystadenomas, especially in premenopausal women. Therefore, CA125 lacks
the specificity to predict ovarian cancer. Moreover, CA125 is limited in the detection of early stage
ovarian cancer, and, in fact, 20% of patients with advanced disease are CA125 negative [15]. Despite
its limitations as a biomarker, CA125 has shown good specificity in combination with an ultrasound
scan in postmenopausal women compared with a single serum test of CA125 alone. Jacobs et al. first
described this algorithm called the risk of malignancy index (RMI) in 1990 [16]. However, both benign
tumours and ovarian malignancies appear in ultrasounds as cystic or solid lesions. The presence
of solid papillations will increase the risk of ovarian cancer from 0.6% in simple cysts to 33% in the
presence of a papillation, according to the International Tumor Analysis Association (IOTA) criteria.
Nevertheless, an ultrasound remains subjective and has to be performed by experienced sonographers.
Even more important is the identification of highly suspicious lesions, which should be treated only
in centres with high numbers of operations for optimal tumour debulking. Optimal debulking, as
indicated by the lack of macroscopically residual lesions, is one of the most important prognostic
factors [17]. It is more likely to be achieved in centres with a high turnover of surgical procedures
performed by experienced gynaecological oncologists. To increase the diagnostic power of these
parameters, human epididymis protein-4 (HE4), another common used biomarker in the serum of
ovarian cancer patients, was used in a newly developed risk of ovarian malignancy algorithm (ROMA)
especially to distinguish patients at a low and high risk of EOC [18].
HE4 detection shows less sensitivity compared with CA125 but exhibits higher specificity for
malignant, rather than benign, conditions and may, therefore, increase diagnostic accuracy along
with CA125 levels and ultrasound scans, respectively [19]. Indeed, significantly more low-volume
cases of stage I and II EOC were identified in a high-risk population of germline mutation carriers in
DNA repair associated breast cancer genes (BRCA) in a recent screening trial [20]. However, current
screening strategies using CA125 velocity did not contribute to the overall reduction of mortality rates
as shown in the UK Collaborative Trial of Ovarian Cancer Screening (UKTOCS) program [21]. Hence,
the discovery of biomarkers, which improve the detection of EOC, is urgently required.
Despite the heterogeneous nature of publicly available gene expression datasets, these have been
instrumental in dissecting the underlying biological processes and pathways of tumor progression and
in the discovery of biomarkers [22–24]. However, inconsistent findings in the biological and clinical
characteristics of molecular signatures often occur as a result of the application of diverse statistical
methods and transcriptional profiling on different platforms [23,25]. Another pitfall is that they are
often limited regarding clinical variables and specific clinical outcomes within available datasets,
preventing them from reaching their full potential to identify prognostic biomarkers or classifiers
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for clinical management. Moreover, the products of overexpressed genes have to be secreted to be
traceable in the bloodstream. Vathipadiekal et al. established a library of secreted genes from publicly
available databases, which allows identification of overexpressed genes encoding secreted proteins [22].
These can serve as blood-based biomarkers or indicate the absence of markers, e.g., in blood. The
library has allowed researchers to validate known biomarkers and identify novel candidates such as
fibroblast growth factor 18 (FGF18) and G-protein-coupled receptor GPR174A (GPR174A) [22].
In the past, tumour biology predominantly focused on epithelial tumour components as sources
of biomarkers. Nevertheless, there is a complex mixture of malignant and non-malignant cells in
multiple peritoneal tumour deposits, which show a dynamic network of paracrine interactions. It has
been reported that the interplay between the network components impacts the overall progression
or regression of the tumour, illustrated by the observation that advanced stages of EOC show a high
stromal to epithelial ratio, which in turn is associated with a poor prognosis [26]. The stroma-epithelial
interactions include soluble factors like chemokines, growth factors, and inflammatory cytokines,
often as a consequence of oncogenic mutations within malignant cells [27–30]. The release of these
factors into the blood has great potential as a biomarker. In general, the stromal compartment has been
insufficiently considered as the origin of novel markers and needs further exploration.
A robust validation of novel biomarkers is extremely resource and time intensive and, thus, only
the biomarkers with strongest prospects of efficacy can be validated. In this study, we have established
a concept for blood-based biomarker discovery to detect ovarian cancer and extend the analysis by
exploring the tumour’s microenvironment. We have used gene expression data obtained from the
analysis of microdissected epithelium and adjacent stroma from benign and malignant serous tumours
(GSE29156) [31], normal epithelium samples (GSE14407) [32], and microdissected cancer stroma
(GSE40595) [33]. We retrieved biomarkers, including both stromal and epithelial specific candidates,
and surveyed a panel of them in the tissue and blood of ovarian cancer patients for their potential as
biomarkers. This method attempts to falsify biomarkers, i.e., identify false positive predictions with
little potential of success. Predictions based on a small number of either transcripts or proteins in the
blood have the potential to be more accurate to predict EOC in clinical management than methods
solely based on CA125, HE4 levels, and ultrasound screenings.
2. Materials and Methods
2.1. Microarray Data and In Silico Analysis
We procured mRNA microarray data sets GSE29156, GSE40595, and GSE14407 from Gene
Expression Omnibus (GEO) database [31–34]. GSE29156 describes microdissected epithelium and
adjacent stroma from 23 benign and 27 malignant serous tumours, whereas GSE14407 contains
expression data for 12 human ovarian cancer samples and 12 normal epithelia samples. Furthermore,
we included the microarray dataset GSE40595, of which we analysed eight normal and 31 cancer
stroma samples by conducting a differential expression analysis between these two sub-cohorts.
All datasets underwent an initial quality control test based on the R-package ‘arrayQualityMetrics’,
version 3.24.0 (doi.org/10.1093/bioinformatics/btn647), and we only utilised samples that passed
the quality thresholds. We normalised probe set expression using the Affymetrix package’s RMA
method (10.1093/bioinformatics/btg405). For GSE29156 and GSE14407, differential gene expression was
calculated between benign and malignant epithelial and stromal tissue, respectively, by application of
an empirical Bayes t-test using the R-package ‘Limma’ (https://doi.org/10.1093/nar/gkv007). Malignant
stromal tissue expression was compared with benign stromal expression and malignant epithelial
expression with benign epithelial expression. In the GSE40595 dataset, the differential expression
was measured between normal and cancerous samples. P-Values were adjusted for multiple testing
using the Benjamini–Hochberg method [35]. Differentially expressed probes were selected on the basis
of meeting the criteria of false discovery rate (FDR) p < 0.01. Probe sets that exhibited an absolute
fold change of greater than two were utilised to generate heatmaps. Two-dimensional hierarchical
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clustering via differentially expressed genes, as well as principal component analysis (PCA) plots, were
produced by the R-package ‘ggplot2′ [36] and heatmap. NanoString data were analysed using the
R-package ‘NanoStringNorm’ [37] and also utilised to create the volcano plots.
2.2. RNA Extraction and Gene Expression Analysis
Whole blood samples from patients with either benign (N = 10) or malignant (N = 10) ovarian
tumours were collected using BD PAXgeneTM Blood RNA System (2.5 mL; Qiagen, Hilden, Germany).
Tubes were gently inverted 5 times directly after collection and incubated for 2 h at room temperature
(RT) and then stored at −80 ◦C until processing. Samples were thawed on ice and left another 2 h at
RT before RNA extraction using the PAXgene RNA extraction kit. All NanoString extractions were
performed according to the manufacturer’s protocol. RNA from frozen tissue was extracted using
Tri Reagent (Sigma, Steinheim am Albuch, Germany), and treated with 10 U DNase (Thermo Fisher
Scientific, Schwerte, Germany). The malignant tumour cell content was assessed by an experienced
clinical gynaecologic pathologist and was between 70–100% in the biopsies of ovarian cancer patients.
Gene expression analysis was performed using the NanoString nCounter Analysis System (NanoString
Technologies, Seattle, WA, USA) with a custom designed codeset containing 48 genes (Supplementary
Table S1). Each reaction contained 250 ng of total RNA in a 5 µL aliquot, plus reporter and capture
probes. Analysis and normalization of the raw NanoString data was performed using nSolver Analysis
Software v1.1 (NanoString Technologies). Raw counts were normalised to the internal expression
levels of beta2-microglobulin (B2M) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We
trained univariate and multivariate logistic regression models utilizing the standard R stats libraries
and employed a logit-link function. The model was trained on tissue and blood samples that were
housekeeping gene normalised.
2.3. Patients Characteristics
All samples used for the PAX gene and gene expression analysis were collected before surgery and
after patients gave their informed consent at the Charité, Department for Gynaecology. The clinical
study was approved by the Local Ethics Committee (EA2/049/13) and conducted according to the
declaration of Helsinki. The serum samples used for enzyme-linked immunosorbent assay (ELISA)
analysis were obtained from the BERLINER study, a prospective, multicentric study, that evaluated
the additive value of HE4 and CA125 to ultrasound, to improve sensitivity and specificity, for the
prediction of ovarian cancer in the pelvic mass patients. For this particular analysis, we only analysed
the samples collected preoperatively at the Department of Gynaecology, Charité Medical University,
Berlin, between 07/2013 and 10/2015, within the discovery cohort.
2.4. Circulatory Levels of Biomarkers by ELISA
Serum CA125 and HE4 protein levels were measured by the standardised method using the Roche
ELecsys Platform at the core facility at Labor Berlin, Charité Medical University Berlin. FGF18 was
quantified using commercially available ELISA kits from MyBiocource (Cat. no. MBS912811). All
assays were performed following the manufacturer’s instructions. Protein levels were measured in
duplicate and the mean values were used for statistical analysis.
2.5. Statistical Analysis
Statistical analysis of in vitro experiments used an unpaired t-test with Welch correction (GraphPad
Prism version 4 Software, Software Inc., San Diego, CA, USA).
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3. Results
3.1. Overview Biomarker Identification Concept
The concept to identify robust stromal biomarkers for the prediction of malignant EOC is shown
in Figure 1. We identified genes differentially overexpressed in both malignant epithelium and
stroma compared with benign control tissue from the GEO mRNA study, GSE29156. An independent
gene expression dataset of ovarian cancer compared with the normal epithelium was included to
expand the analysis. To assure that the differentially expressed genes encoded secreted proteins, we
further restricted the list of candidates to those that were reported to be secreted by the secretome
database of Vathipadiekal et al. The recently suggested biomarker FGF18 (3.6 fold) could be replicated.
The biological processes that involve the biomarker candidates and distinguish malignant from
benign EOCs were uncovered by a Gene Set over-representation analysis (GSOA) and could be
classified as biologically plausible (Supplementary Figure S1). The top 25% of the Log-FC sorted 152
biomarkers candidates were validated on transcript levels in patient-derived tissue and serum with
either malignant or benign tumours by NanoString analysis (Figures 2 and 3, Supplementary Figures
S2 and S3). Finally, the measured validation expression levels were compared to those entered in the
independent CSIOVDB database (Ovarian cancer database of Cancer Science Institute Singapore) for
confirmation (Figures 4 and 5).
Figure 1. Overview of the biomarker identification concept. Three independent studies for genes
over-expressed in malignant tissue were interrogated (Gene Expression Omnibus (GEO) series GSE29156,
GSE40595 and GSE14407). Genes found to be over-expressed in both studies while simultaneously being
secreted into the bloodstream were defined as biomarker candidates using the secretome database (DB).
The candidates’ expression signatures in tissue and blood were measured by NanoString analysis and
enzyme-linked immunosorbent assay (ELISA), respectively and compared to the reported signatures in
the CSIOVDB database (Ovarian cancer database of Cancer Science Institute Singapore) to determine
whether the measured signatures could be independently replicated. Versican (VCAN), syndecan-3
(SDC3), aurora kinase A (AURKA) and T-cell differentiation protein myelin and lymphocyte (MAL)
were confirmed as potential biomarkers, but not claudin-6 (CLDN6) by this analysis.
3.2. Detailed Description of the Identification Workflow
We pre-selected candidate biomarkers by analysis of published datasets and chose the mRNA-array
GEO dataset GSE29156 [18] due to its focus on stromal tissue. Expression data from samples that were
classified as healthy, benign, and malignant were available, with measurements of both the stromal
compartment and epithelium. We compared (I) epithelium, (II) adjacent stroma, and (III) the complete
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transcriptome of 23 benign and 27 malignant samples and created lists of differentially expressed
biomarker candidates provided in Supplementary Table S2.
Early detection biomarkers have to be both lowly expressed under normal and benign conditions
and specifically elevated in the blood of ovarian cancer patients. To ascertain if candidate biomarkers
fulfilled these conditions, we utilised a novel virtual secretome array consisting of 16,521 Affymetrix
probe sets. We used this secretome array as the search space for potential candidates, using a more
stringent cut off value of significantly overexpressed genes associated with malignant tumours (twofold;
p < 0.01) to reduce the false positive rate. The lists of differentially expressed genes for the compartment
specific signatures included 170 (I) (cut off twofold; p < 0.01) including 74 higher expressed in malignant
epithelium and 193 genes (II) with 58 of them higher in the stroma of malignant biopsies, respectively.
In our initial analysis, we found a unique set of 30 proteins within the secretome using either of the
compartment specific gene lists. Using the total dataset with stromal and epithelial data combined to
compare benign with malignant serous tumours, we identified 831 differentially expressed genes (III),
with 268 of them higher in the ovarian cancer samples. A further 122 genes were detected when the
more comprehensive gene list of genes was used in the same manner. Taken together, 152 genes were
identified to be overexpressed in the mRNA expression dataset of malignant tumours compared with
benign tumours, which could be potentially secreted into the bloodstream (Supplementary Table S3).
Moreover, we included the gene expression data set GSE40595 [33], which contains microdissected
normal and cancer stroma samples in the analysis, and found that 6103 genes were differentially
expressed with higher expression levels in the malignant stroma compartment compared with normal
controls (twofold; p < 0.01), with 81 (53%) of them also within the 152 gene signature.
A GSOA of the 152 secretome gene signature revealed the signature’s significant association with
the processes and pathways found in ovarian cancer (Supplementary Figure S1). The expression
levels of genes involved in extracellular matrix remodeling and integrin binding showed the highest
overrepresentation in the malignant cases. Furthermore, we found increased levels of gene expression
for members in the FGF, PI3K, and PDGF signalling pathways and downstream-regulated transcription
factor (TF) signalling of activator protein 1 (AP1) and nuclear factor-κB (NF-κB) in biopsies of ovarian
cancer compared with benign tumours. Other identified genes enriched in ovarian cancer belonged to
the calcium regulation of molecular function categories, cholesterol metabolism, and the oxidative
stress pathway.
Subsequently, the GSE14407 [32] mRNA dataset, comprising 12 normal and 12 ovarian cancer
samples, was analysed to independently support or refute the candidate biomarkers. Between the
groups, 3503 genes were differentially expressed (twofold; p < 0.01); 446 of them were higher in the
ovarian cancer samples. The expression data were filtered for genes in the list of 152 biomarker
candidates from the first gene expression analysis. 16 of them were identified to be more highly
expressed in both the GSE40595 and GSE29156 datasets associated with ovarian cancer and found
in the secretome array. Among them were nuclear orphan receptor NR2F6 (NR2F6), denticleless E3
ubiquitin protein ligase (DTL), myelin and lymphocyte protein (MAL), aurora kinase A (AURKA),
fibroblast growth factor 18 (FGF18), maternal embryonic leucine zipper kinase (MELK), syndecan-3
(SDC3), and versican (VCAN).
3.3. Assessment of Biomarker Candidates in Tissue and Blood
To verify our findings we determined the mRNA expression levels of the top 25% (N = 38 genes)
of 152 biomarker candidates in benign (N = 10) and malignant tumour (N = 10) biopsies by NanoString
analysis. A further 10 genes were included for gene expression analysis according to the findings in
the second dataset (GSE14407) associated with ovarian cancer and present in the list of 152 biomarker
candidates within the secretome array. 56% of this list of 48 genes were also significantly overexpressed
in the cancer stroma within the GSE40595 data set.
A principal component analysis (PCA) (Figure 2) of the pair-wise sample correlations supported
the pathological classifications of the samples and the existence of differentially expressed genes,
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(Supplementary Figure S2). A PCA using the 48 gene signature showed a strong classification of benign
and malignant samples, with the exception of one sample derived from a patient with low grade serous
ovarian cancer (LGSOC), which presented a greater similarity with benign gene expression profiles.
Genes differentially expressed between the shown cohorts were identified by a differential expression
analysis (Figure 3A,B).
We expanded our study to include the gene expression profiles of the same panel of genes using
mRNA samples from the blood of patients with benign conditions and ovarian cancer. No candidate
biomarker was significant for differential expression. However, VCAN and SDC3 transcripts were
elevated in the blood of ovarian cancer patients and showed a considerable trend toward significance
(Supplementary Figure S3, P-values: VCAN = 0.052, SDC3 = 0.055).
We next estimated the predictive performance of the twelve genes whose expression was quantified
in the tissue, as well as the performance of VCAN, shown in Supplementary Material Table S4. To
that end, we trained a logistic regression model and predicted whether a sample was malignant or
benign for each single gene by itself and once together, based on all twelve blood quantified genes. We
observed that the predictive power in the tissue-derived NanoString quantified data was high, with
an average sensitivity, specificity, and positive predictive value (PPV) of 88%, while the full model
achieved a perfect predictive performance based on the tissue-derived data. The models trained on
blood-derived data showed a reduced predictive power, with an average sensitivity of 68%, a specificity
of 58%, and a PPV of 66%, and the full model achieved a sensitivity of 90%, a specificity of 70%, and a
PPV of 75%.
Figure 2. Principal component analysis (PCA) of patient-derived malignant and benign samples. Data
from malignant and benign samples supported the pathological sample classification as malignant or
benign since the sample were separable along the principal component 1 (PC1) of a principal component
analysis (PCA) of their pairwise correlation. Their separability allowed identification of differentially
expressed biomarker candidates to distinguish between benign and malignant samples.
3.4. Validation of Biomarkers in Serum
Since a high signal-to-noise ratio would increase the specificity of a biomarker in the detection
assay, we analysed the protein expression of candidates in normal adult tissue using the human
Proteome Map [38]. In order to validate the most promising biomarkers, based on the results of the
PCA and volcano plot combined with the normal distribution pattern (Supplementary Figure S4), we
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decided to test the protein expression levels of the recently reported novel biomarker FGF18 in serum
from women with a pelvic mass who were scheduled to have surgery.
The preoperative serum of patients with either ovarian cancer (N = 60) or common benign
gynaecological conditions (N = 56) was included in this study. A detailed description of the patient
cohort is shown in Table 1. First, we measured the most widely used tumour markers, CA125 and HE4,
to compare against the newly suggested biomarker, FGF18, in terms of sensitivity and specificity. Both
CA125 and HE4 levels were significantly elevated (p < 0.0001) in the serum of ovarian cancer patients
in our study cohort (Supplementary Figure S5A,B). In the same samples, FGF18 protein expression
levels were either not detected or were not significantly increased compared to serum from patients
with benign neoplasia (p = 0.43) (Supplementary Figure S5C). However, FGF18 levels raised according
to tumour stage (p = 0.0054) but were not correlated with any other clinical parameters like pre- and
postmenopausal status, age, or tumour burden (data not shown).
Figure 3. Validation of biomarker candidates in tissue and blood. (A) This plot depicts the Log–Fold
changes and P-values of differential biomarker expression values between malignant (positive values)
and benign tissue (negative values). The top 10 significant (P-value significance ≥ ~1.3) candidate
biomarkers are labelled. (B) The distribution of gene expression levels of biomarker candidates matrix
metalloproteinase 15 (MMP15), bone morphogenetic protein 7 (BMP7), denticleless E3 ubiquitin protein
ligase (DTL), maternal embryonic leucine zipper kinase (MELK), complement factor B (CFB), nuclear
orphan receptor (NR2F6), galactoside 2-alpha-L-fucosyltransferase-2 (FUT2), claudin-6 (CLDN6),
aurora kinase A (AURKA), interferon-stimulated gene 15 (ISG15), myelin and lymphocyte protein
(MAL), fibroblast growth factor 18 (FGF18) in benign and ovarian cancer tissues are shown (p < 0.05).
The expression data were obtained by NanoString analysis using the mRNA from tissue samples of
patients with benign (N = 10) disease or ovarian cancer (N = 10).
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Table 1. Clinico-pathological parameters of the patient cohort.
Clinical Parameters Tissue Blood Serum
Benign pelvic tumours
Age at first diagnosis (median/range) 49 (25–68) 69 (41–92) 47 (23–79)
CA125 (U/mL) mean (range) 72 (12–278) 18 (6–77) 28 (5–215)
He4 (pM) mean (range) 44 (32–78) 52 (30–90)
Histology (*)
Cystadenoma 3 (33%) 2 (20%) 19 (33.9%)
Dermoid cyst 3 (33%) 2 (20%) 12 (21.4%)
Endometriosis 2 (20%) 4 (40%) 8 (14.4%)
Functional cysts 2 (20%) 1 (10%) 4 (7.1%)
Myoma uteri 2 (20%) 1 (1.8%)
Benign Brenner tumour 1 (1.8%)
Cystadenofibroma 4 (7.1%)
Fibroma 2 (3.6%)
Others 2 (20%) 5 (8.9%)
Ascites
Present 1 (10%) 3 (5.4%)
Absent 9 (90%) 10 (100%) 52 (92.9%)
NA 1 (1.7%)
Ovarian Cancer
Age at first diagnosis (median/range) 61 (48–79) 58 (29–86) 62 (22–79)
CA125 (U/mL) mean (range) 1046 (12–6193) 600 (10–3331) 1124 (8–11616)
He4 (pM) mean (range) 341 (49–1305) 892 (97–3136) 637 (47–4676)
Histology
High grade serous 6 (60%) 9 (90%) 46 (76.7%)
Low grade serous 1 (10%) 1 (1.7%)
Endometrioid 1 (10%) 9 (15.0%)
Mucinous 1 (10%) 1 (1.7%)
Clear cell 1 (10%) 1 (10%) 2 (3.3%)
Others 1 (1.7%)
Grading
G1 3 (30%) 7 (11.7%)
G2–3 7 (70%) 10 (100%) 53 (89.3%)
FIGO Stage (**)
I–II 2 (20%) 12 (20.0%)
III–IV 7 (70%) 10 (100%) 48 (80.0%)
NA 1 (10%)
Ascites
Present 6 (60%) 7 (70%) 32 (53.3%)
Absent 4 (40%) 3 (30%) 28 (46.7%)
* One patient had both uterus myomatosus and a functional cyst, one patient had endometriosis and cystadenoma,
and another patient had both a dermoid cyst and cystadenoma. ** Fédération Internationale de Gynécologie et
d’Obstétrique (FIGO).
3.5. Exploration of Potential Diagnostic Markers Using a Gene Expression Database
We queried the gene expression database CSIOVDB for whether the measured expression levels
could be replicated independently [39]. The expression of selected biomarker candidates in healthy
tissue (Figure 4A) was compared, as well as expression in ovarian cancer stroma (Figure 4B).
In particular, SDC3 and VCAN could be successfully replicated and were significantly
overexpressed in tumour stroma compared to healthy stroma. NR2F6, DTL, MAL, and MMP15
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could also be successfully replicated. However, they showed significantly higher P-values and lower
Log-FCs. Notably, FGF18 and AURKA were specifically overexpressed in the malignant epithelium.
Apart from VCAN, SDC3, and MMP15, gene expression of these markers was increased with
the grade and stage of the disease, regardless of the major subtypes significantly elevated in EOC
(http://csibio.nus.edu.sg/CSIOVDB/CSIOVDB.html). On the other hand, genes like CLDN6 and CFB
were not confirmed as potential biomarkers by this analysis.
Among all the investigated genes, AURKA and MAL expression levels showed the best correlation
with progression free survival (PFS) and the overall survival (OS) of ovarian cancer patients, and
high expression levels were associated with a poor prognosis. The correlation of AURKA and MAL
expression levels with PFS and OS for patients with ovarian cancer is shown in Figure 5 as an example
(Figure 5B,D). The Kaplan–Meier plots were obtained according to the low and high expression of
AURKA and MAL and analysed using a log rank P-value calculated and displayed on the webpage.
Given the central role of the fallopian tube as a cell-of-origin source for a large proportion of
high-grade serous ovarian cancer (HGSOC), we also compared the gene expression levels of candidates
in the ovarian cancer epithelium with fallopian tube epithelium (FTE) expression. Only the stromal
derived genes, VCAN and SDC3, as well as MMP15, were not found to be significantly overexpressed
in this analysis, whereas all other candidates showed a strong significance (p-value <0.0001) and were
associated with the malignant ovarian epithelium. Distribution in the gene expression of AURKA
and MAL in FTE samples is shown in comparison with expression levels in other compartments in
Figure 5A,C (Figure 5).
4. Discussion
Detection of EOC is urgently required to improve its prognosis and save the lives of women
worldwide. The need persists for a differential diagnosis that distinguishes pelvic mass patients with
either benign gynaecological conditions (including benign tumours and cysts) or EOC. CA125 is still
the most common serum biomarker used clinically to detect EOC, despite its limitations, specifically
due to fact that it is associated with the menstrual cycle and stages during pregnancy. It can also be
overexpressed by inflammation and in common gynaecological conditions, such as endometriosis [40].
Therefore, biomarkers based on detecting ovarian cancer specifically in blood-based assays need to be
validated in a clinical context with benign and malignant gynaecological conditions. Sensitivity is also
an issue since not all ovarian cancer expresses CA125.
Many studies report the discovery of different potential biomarkers, but most of them do not
meet the criteria of sensitivity and specificity [4,41–45]. However, no biomarkers outperformed
CA125 [46,47]. One strategy to improve these parameters is to use the combinatorial power of different
biomarkers. Especially in the light of inter- and intra-tumour heterogeneity, multiple tumour-specific
molecules might be needed for detection. Further, the contribution of the tumour microenvironment
in response to the process of malignant transformation and in tumour progression has often been
neglected and needs further evaluation.
In addition, several of the proposed biomarkers have not been thoroughly validated, which entails
a lack of information on the history of the samples, as well as standard operating procedures for
sample selection, collection, and storage. Moreover, validation studies frequently compare healthy
and diseased cohorts, which often do not match by age [2,12]. Therefore, in our study we used well
controlled serum samples from patients with a pelvic mass (N = 56, benign gynaecological conditions
and N = 60, ovarian cancer) undergoing a surgical procedure at the Department of Gynaecology at
the Charité in Berlin. To be able to compare the performance of novel candidates with established
markers CA125 and HE4 in predicting ovarian cancer, we first determined the levels of CA125 and
HE4 in our cohorts.
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Figure 4. Reported biomarker expression. Log–Fold change of biomarker candidates are shown for
two sets of cohorts; (A) healthy ovarian surface epithelium (OSE) versus ovarian cancer (OVCA) and
(B) healthy versus cancerous stromal tissue. P-values higher than 1.3 are significant (horizontal line).
Genes have been ranked according to their P-values in the OSE versus OVCA comparison from highest
to lowest statistical power. Data have been procured from the CSIOVDB database [39]. Both plots show
the same genes but are differently ordered by increasing the P-value. Differentially expressed biomarker
candidates that distinguish malignant from healthy tissues are clearly present in plot A. By comparison,
significantly fewer biomarkers that distinguish malignant from benign tissue are identifiable on plot
B. In particular, the P-values for differential expression are significantly higher on plot B, although
VCAN, ISG15, and MAL show a comparable Log–Fold change, which indicates a higher variance, i.e.,
expression heterogeneity within the groups.
Here, we queried publicly available gene-expression data of microdissected stroma and epithelial
tissue to identify novel stroma-based biomarkers that discern ovarian cancer tissue from benign
gynaecological conditions [18]. By filtering for genes differentially expressed not only between
malignant and benign epithelial tissue but also between stromal tissue, we identified 152 novel
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biomarker candidates involved in the processes and pathways that differentiate ovarian cancer from
benign gynaecological conditions.
Dysregulation and increased activity of the FGF, PDGF, and PI3K pathways were strongly
associated with malignant tumours, and, therefore, a significant fraction of the biomarker candidates
was associated with these processes. Increased activity of these pathways is supported by recent
findings, e.g., with respect to PI3K, which is reported as being activated in up to 50% of high-grade
serous ovarian cancers (HGSOCs) [5,22]. Furthermore, biomarker candidates show a high degree of
connectivity due to their common involvement in the transcriptional regulation programs of AP1
and NFκB.
Since a significant fraction (53%) of the 152 gene signature were found also to be increased
in malignant stroma compared with normal control samples, one can speculate that a substantial
proportion of the biomarker candidates are part of a stroma response to cancer progression. This result
shows once again the value of this compartment as a source for biomarker discovery.
Only biomarkers with the strongest prospect of efficacy can be validated in subsequent high-sample
size studies due to cost and resources. Therefore, attempts to falsify biomarkers, i.e., identify false
positive predictions with little potential of success, is imperative. To assess the real-world efficiency
of the 152 biomarker candidate panel, we restricted this list by selecting 48 genes, which were
simultaneously secreted according to a comprehensive secretome database, within the top 70th
percentile of Log-FCs with the greatest potential [22].
Estimation of the false positive candidates was based on NanoString analysis and performed on
tissue and the peripheral blood of patients with EOC and benign gynaecological conditions. 12 genes
were significantly differentially expressed in tissue with an expression at least twice as high in malignant
samples. The top genes were MMP15, DTL, MELK, CLDN6, AURKA, and MAL (Figure 3). FGF18 was
also significantly overexpressed but to a lower degree. We did not find any of the stromal specific genes
to be significantly differentially expressed within the tissue. This is possibly because the malignant
cell content of >70% within the tissue samples induced a bias towards genes differentially expressed
within the epithelium. In contrast, we did not find genes from the malignant epithelium, but transcript
levels showed the stroma-derived genes, VCAN and SDC3, to be elevated in the blood of patients with
EOC. Although the results obtained in blood fell short of significance by a narrow margin (P-value
VCAN 0.052, SDC3 0.055, Supplementary Figure S3) the impact of the tumour microenvironment has
to be taken into account since both genes are also expressed in other cell types, such as macrophages,
endothelial cells, and fibroblasts [48–50].
Even though the utilised sample size of ten candidates for each condition is not sufficient for a
clinical validation in the context of a false-positive biomarker candidate exclusion study, as described
above, it can be considered sufficient. An optimal choice of technology, e.g., either miRNA or protein
detection in conjunction with an increased sample size can be reasonably assumed to render the
markers’ performance significant. However, the purpose of this study is to identify and exclude
markers whose validation is not promising and to report marker candidates that show potential for
being effective markers despite a limited sample size and unoptimised technology. Notably, VCAN and
SDC3 overexpression signatures were independently replicated by querying the CSIOVDB. Stromal
VCAN expression is induced by TGFβ and IL6 and has been shown to regulate processes like tumour
growth and invasion. Furthermore, VCAN expression levels correlate with tumour progression and
are a strong prognostic indicator, particularly in stage II colon cancer [51]. Therefore, VCAN has the
potential to become a promising biomarker for ovarian cancer. Syndicans are another class of secreted
extracellular matrix glycoproteins that have an important role in cancer development and prognostic
value in various tumours, including ovarian cancer [52,53].
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Figure 5. Gene-expression in ovarian cancer. Gene expression profiles of (A) AURKA and (C) MAL in
normal tissue, including ovarian surface epithelium (OSE), stroma and fallopian tube epithelium (FTE),
and the ovarian cancer disease state are shown. The correlation of gene expression with the PFS and
OS of ovarian cancer patients is presented in (B,D), respectively. Kaplan–Meier plots were generated
with samples of low (blue) and high (red) gene expression levels within the CSIOVDB dataset.
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The protein levels of CA125 and HE4 within blood were significantly elevated in patients with
ovarian cancer compared to benign conditions (Supplementary Figure S5A,B). However, FGF18 was
not confirmed as a biomarker in our sample cohort. It is important to point out that the previous ELISA
validation study by Vathipadiekal et al. was performed on a small number of serum samples from
late stage III/IV patients compared with samples from normal probands [22]. Nevertheless, FGF18
protein levels correlated with disease status in our study and increased with tumour progression
(Supplementary Figure S5C).
From the set of genes we found to be dysregulated and associated with malignant ovarian cancer,
AURKA and MAL seemed to have the greatest impact on OS. Aberrant Aurora-A kinase activity has
been generally implicated in oncogenic transformation and tumour progression [54]. Furthermore,
it has not only been shown to be a therapeutic target in several different cancer types but to also
have potential as a biomarker in colorectal, gastrointestinal, and bladder cancer [55–57]. MAL has
been shown to regulate proliferation and mediate platinum resistance in EOC [58]. Overexpression of
MAL is an independent predictor of poor survival and is, in particular, a feature of HGSOC and other
subtypes of EOC [59,60]. Since AURKA and MAL have been implicated in ovarian cancer pathology
and are, therefore, functionally important rather than the outcome of a deregulation side effect, they
are promising nominees to include in a panel of novel biomarkers for the detection of ovarian cancer.
As a result, the measurement of two or more transcripts obtained by PAXgene tubes in blood has
the potential to be more reliable and robust in the prediction of overall survival and merely requires
a direct draw into the tubes to minimise RNA degradation at room temperature. This analytical
validation of real-time reverse transcription polymerase chain reaction (RT-PCR) based assays to
detect transcripts was performed using tissue and peripheral blood from metastatic prostate cancer
patients [4]. However, further evaluation of the transcript levels in blood needs to be performed on a
bigger cohort of patient samples. Since multiplex technologies such as NanoString gene expression
assays can analyse a large number of different biomarkers in a single experiment, the study should
be expanded to include the entire 152 gene signature we identified to be significantly overexpressed
in malignant, compared with benign, tumours while being secreted. In this context, it is worth
mentioning that there are many reasons why the results obtained from tumour tissue are different
from the transcript levels in blood and are not detected there. One obvious answer is the issue of
degradation from release until detection in a sensitive blood-based assay. Moreover, in contrast to their
products, mRNA is not actively released or secreted. Thus, a direct correlation between blood-based
assays and transcript levels might not always be possible. Therefore, it would be more relevant to
assay the protein levels of the top candidates in blood, rather than RNA, but this is beyond the scope
of the current study.
In summary, several markers showed substantially elevated expression levels between ovarian
cancer compared with benign conditions in publically available expression data and our proof of concept
study (including recently suggested marker FGF18) for ovarian cancer prediction [22]. Nevertheless,
mRNA expression did not necessarily translate into protein levels (Supplementary Figure S5). Further
candidates of novel biomarkers for validation by ELISA should be selected based on high values of
gene expression and P-values in ovarian cancer tissue and blood by NanoString analysis (Figure 3,
Supplementary Figures S2 and S3), as well as low or absent protein expression in a healthy cohort [38].
While MMP15 was still significantly overexpressed in ovarian cancer biopsies, CLDN6 did not meet
these criteria in a bigger cohort (Figure 4A). In support of those findings, MMP7 has already been
reported to be a suitable biomarker in EOC [44]. Moreover, NR2F6, DTL, MAL, and AURKA showed
greater differential expression than MMP15 and FGF18 in the epithelium of EOCs and hence might
have greater potential as biomarkers as their evaluation can prove advantageous.
It should be mentioned again that all utilized discovery gene expression datasets analysed in
this study were generated using biopsies of HGSOC patients. However, it is now clear that the term
‘ovarian’ cancer refers to at least four distinct diseases, all of which grow and spread within the
peritoneal cavity and ovary. However, by querying the extensive CSIOVDB database with microarray
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data from over 3000 EOC biopsies, including profiling the stromal compartments to analyse those
independently, the identified candidates were significantly increased across all EOC subtypes and
were, therefore, not only exclusively relevant to HGSOC.
Although the fallopian tube is thought to be the most common place of origin for ovarian cancer,
OSE cannot be ignored, as not all HGSOC cases can be explained as an evolution from serous tubal
intraepithelial carcinomas (STICs). Due to the lack of gene expression data for FTE in the discovery
datasets, biomarker candidates were identified by comparing the gene expression profiles of ovarian
cancer with microdissected normal and benign OSE and, for consistency, were presented using the
comprehensive database CSIOVDB (Figure 4A). Since FTE data were available in this database, a
comparison of cancer epithelium versus FTE was also included and, apart from the stromal derived
candidates VCAN and SDC3, as well as MMP15, all other discovered biomarkers were associated
with EOC and increased with tumour progression. Although there are no gene expression profiles
available for benign tumours, it is worth noting that we do not aim to validate, but rather determine
biomarker candidates with the greatest potential of success utilising the CSIOVDB database. These
would then need to be validated in subsequent follow-up studies in the serum of patients with benign
gyneacological conditions and EOC.
Further studies will focus on the evaluation of AURKA and MAL in combination with a panel
of candidates with the substantial differential expression identified in this study. This will include
genes such as VCAN and SDC3 from the stromal compartment for the detection of EOC in blood
based assays.
5. Conclusions
The aim of the study was to render a differential diagnostic approach possible the discovery novel
biomarker candidates across all major subtypes of EOC. We have established a concept for blood-based
biomarker discovery to detect ovarian cancer and extended the analysis by exploring the tumour
microenvironment, because the stroma represents a viable source of biomarkers, but often neglected.
We retrieved novel biomarker candidates from public databases, including both stromal and epithelial
specific. We provide evidence that the tumour stroma might be a useful source for biomarker discovery
to predict EOC. The identified candidates should be included and subject of future biomarker research
also for early detection of EOC.
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